NASDAQ:APVO

Aptevo Therapeutics (APVO) Stock Forecast, Price & News

$1.56

0.00 (0.00%)

(As of 06/1/2023 ET)

Compare

Today's Range: $1.51
▼
$1.61
50-Day Range: $1.56
▼
$2.08
52-Week Range: $1.51
▼
$7.20

Volume: 73,654 shs
Average Volume: 66,690 shs
Market Capitalization: $11.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Aptevo Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 728.0% Upside
$13.00 Price Target
Short Interest: Healthy
0.97% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.24) to ($4.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

1729th out of 1,980 stocks

Pharmaceutical Preparations Industry

869th out of 978 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $13.00, Aptevo Therapeutics has a forecasted upside of 728.0% from its current price of $1.57.
Amount of Analyst Coverage
Aptevo Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.97% of the outstanding shares of Aptevo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aptevo Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptevo Therapeutics has recently decreased by 47.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aptevo Therapeutics does not currently pay a dividend.
Dividend Growth
Aptevo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APVO.

2.5

News and Social Media Coverage

News Sentiment
Aptevo Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aptevo Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
4 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Aptevo Therapeutics is held by insiders.
Percentage Held by Institutions
Only 17.04% of the stock of Aptevo Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aptevo Therapeutics are expected to decrease in the coming year, from ($3.24) to ($4.91) per share.
Price to Book Value per Share Ratio
Aptevo Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Stock News Headlines

May 27, 2023 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

May 19, 2023 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com

June 1, 2023 | Edge On The Street (Ad)

AI Getting Close to Thinking Like Humans

Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.

May 14, 2023 | americanbankingnews.com

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Growth in Short Interest

May 12, 2023 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com

May 11, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

May 9, 2023 | americanbankingnews.com

Aptevo Therapeutics (APVO) Scheduled to Post Earnings on Wednesday

May 3, 2023 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

June 1, 2023 | Edge On The Street (Ad)

AI Getting Close to Thinking Like Humans

April 6, 2023 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Upgraded at StockNews.com

April 1, 2023 | finance.yahoo.com

Aptevo Therapeutics Full Year 2022 Earnings: EPS Beats Expectations

March 30, 2023 | finance.yahoo.com

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

March 30, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

January 9, 2023 | finance.yahoo.com

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

December 20, 2022 | finance.yahoo.com

Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate

December 14, 2022 | benzinga.com

Short Volatility Alert: Aptevo Therapeutic

December 12, 2022 | finance.yahoo.com

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

November 10, 2022 | finance.yahoo.com

Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 9, 2022 | finance.yahoo.com

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

November 3, 2022 | finance.yahoo.com

Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

October 1, 2022 | seekingalpha.com

APVO Aptevo Therapeutics Inc.

September 19, 2022 | finance.yahoo.com

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

August 11, 2022 | finance.yahoo.com

Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 4, 2022 | nasdaq.com

Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates

June 17, 2022 | msn.com

Aptevo Therapeutics's Return On Capital Employed Overview

June 11, 2022 | seekingalpha.com

Aptevo gains after disclosing additional remission data in leukemia trial

June 9, 2022 | finance.yahoo.com

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

See More Headlines

APVO Price History

30 days | 90 days | 365 days | Advanced Chart

APVO Company Calendar

Last Earnings: 5/11/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APVO
CUSIP: N/A
CIK: 1671584
Web: www.aptevotherapeutics.com
Phone: (206) 838-0500
Fax: 206-838-0503
Employees: 54
Year Founded: 2016

Price Target and Rating

Average Stock Price Forecast: $13.00
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +729.5%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $8.03 million
Net Margins: N/A
Pretax Margin: 225.24%
Return on Equity: -102.29%
Return on Assets: -58.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.91
Quick Ratio: 4.91

Sales & Book Value

Annual Sales: $3.11 million
Price / Sales: 3.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.19 per share
Price / Book: 0.49

Miscellaneous

Outstanding Shares: 7,290,000
Free Float: 7,020,000
Market Cap: $11.43 million
Optionable: Optionable
Beta: 5.33

Social Links

Key Executives

Marvin L. White
President, Chief Executive Officer & Director

Jeffrey G. Lamothe
Chief Operating Officer & Executive Vice President

Daphne L. Taylor
Chief Financial Officer & Senior Vice President

Dirk Huebner
Chief Medical Officer

Miriam Weber Miller
Investor Relations Contact

Key Competitors

View All Competitors

Institutional Ownership

Renaissance Technologies LLC
Sold 10,500 shares on 5/12/2023
Ownership: 0.759%

View All Institutional Transactions

APVO Stock - Frequently Asked Questions

What is Aptevo Therapeutics' stock price forecast for 2023?: 0 equities research analysts have issued twelve-month price targets for Aptevo Therapeutics' stock. Their APVO share price forecasts range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next year. This suggests a possible upside of 729.5% from the stock's current price.
View analysts price targets for APVO or view top-rated stocks among Wall Street analysts.
How have APVO shares performed in 2023?: Aptevo Therapeutics' stock was trading at $2.32 at the start of the year. Since then, APVO stock has decreased by 32.4% and is now trading at $1.5673.
View the best growth stocks for 2023 here.
Are investors shorting Aptevo Therapeutics?: Aptevo Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 71,000 shares, a drop of 47.6% from the April 30th total of 135,500 shares. Based on an average daily volume of 53,100 shares, the days-to-cover ratio is currently 1.3 days.
View Aptevo Therapeutics' Short Interest.
When is Aptevo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our APVO earnings forecast.
How were Aptevo Therapeutics' earnings last quarter?: Aptevo Therapeutics Inc. (NASDAQ:APVO) released its earnings results on Thursday, May, 11th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.19) by $1.45.
What other stocks do shareholders of Aptevo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?: Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."
Who are Aptevo Therapeutics' major shareholders?: Aptevo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.76%).
View institutional ownership trends.
How do I buy shares of Aptevo Therapeutics?: Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aptevo Therapeutics' stock price today?: One share of APVO stock can currently be purchased for approximately $1.57.
How much money does Aptevo Therapeutics make?: Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $11.43 million and generates $3.11 million in revenue each year.
How can I contact Aptevo Therapeutics?: Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503.

This page (NASDAQ:APVO) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial